Navigation Links
Pharmasset to Present at Deutsche Bank Healthcare Conference
Date:5/14/2009

PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Deutsche Bank 34th Annual Healthcare Conference. The conference will be held in the InterContinental Boston Hotel, Boston, MA (May 18 to 19).

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the Company at the conference on Monday, May 18, 2009 at 2:25 PM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

        Pegasys(R) and Copegus(R) are registered trademarks of Roche.

        Contact
        Richard E. T. Smith, Ph.D.
        VP, Investor Relations and Corporate Communications
        richard.smith@pharmasset.com
        Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended March 31, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset to Present at Two Upcoming Investor Conferences
3. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
4. Pharmasset to Webcast an Investor Event from the AASLD Meeting
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
7. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
8. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
9. Pharmassets Underwriters Release Shares from Lock-Up
10. Medco to Present at the Deutsche Bank 34th Annual Health Care Conference
11. Perforomist Inhalation Solution data to be presented at American Thoracic Society conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... September 26, 2017 , ... DETECTO has been ... 1, 2017, the new agreement allows Premier members, at their discretion, to take ... “DETECTO is pleased to renew our agreement with Premier to be able to ...
(Date:9/26/2017)... ... ... “The Ballad of Cowboy Justin”: a charming tale of a brave cowboy who ... creation of published author, Leah Westbrook, a wife and mother who loves to spend ... a delightful tale about a young brave cowboy, Cowboy Justin, who saves the town ...
(Date:9/26/2017)... ... ... Guide”: is the life story of the author and the exciting times this adventurer has ... an adventure tour guide and the subject of the book. , “Quickly slapping a ... faces. I played it off as a part of the adventure tour, an “added bonus” ...
(Date:9/25/2017)... (PRWEB) , ... September 26, 2017 , ... Your World ... in February 2017 and began fulfilling a life-long wish of owner Stacy Boyle to ... was a recipient of help when I was in high school,” said Ms. Boyle. ...
(Date:9/25/2017)... ... 25, 2017 , ... The Renal Support Network (RSN) is proud to announce ... enhanced rich content focused on RSN’s mission to empower people who have kidney disease ... future. , Our unique website is loaded with hundreds of exclusive personal stories. ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
Breaking Medicine Technology: